China
Africa
Explore chapters and articles related to this topic
Trace Mineral Deficiencies – Diagnosis and Treatment
Published in Jennifer Doley, Mary J. Marian, Adult Malnutrition, 2023
Kavitha Krishnan, Julianne Werner
A dosage of 150–200 mg/d of elemental iron for three months is recommended to treat iron deficiency.25 Iron is most commonly available in the form of ferrous sulfate, ferrous gluconate and ferrous fumarate. Although fumarate is most easily absorbed, sulfate and gluconate forms are preferred since they are inexpensive, and are also bioavailable.2 The amount of elemental iron in each iron salt varies, hence the type of the supplement will determine the dosage. Ferrous sulfate is 20% elemental iron, ferrous fumarate 33%, and ferrous gluconate 12%.26
Anemia (Microcytic)
Published in Charles Theisler, Adjuvant Medical Care, 2023
Iron: In most cases, oral administration of iron therapy with soluble iron salts (Fe2+ sulfate, succinate, lactate, fumarate, glycine sulfate, glutamate, and gluconate, since all are about equally absorbed) at a dose of 325 mg two to three times a day is appropriate. It is generally recommended that approximately 200 mg of elemental iron be administered daily.2
Maternal Anemia
Published in Vincenzo Berghella, Maternal-Fetal Evidence Based Guidelines, 2022
Ashley E. Benson, Marcela C. Smid
Except in women with hemochromatosis or other genetic disorders, there is little evidence of morbidity associated with iron supplementation. Common side effects of oral supplementation include constipation and gastrointestinal upset. The recommended daily allowance of ferrous iron during pregnancy is 27 mg, which is present in most prenatal vitamins [1]. Table 14.9 lists elemental iron content of available iron supplements.
Synbiotic Supplementation Improves Response to Iron Supplementation in Female Athletes during Training
Published in Journal of Dietary Supplements, 2022
Amanda Sandroni, Elaine House, Lindsay Howard, Diane M. DellaValle
In the current study, as mentioned, we had very good compliance in both groups over the course of the study. Athletes in the Placebo group consumed 93.4 ± 12.8% of their assigned packets and 87.5 ± 14.0% of their FeSO4. Athletes in the Treatment group consumed 90.9 ± 11.4% of their assigned packets, and 86.4 ± 9.6% of their FeSO4. So, although athletes in both groups consumed on-average ∼ 87% of the prescribed Fe dose (∼97 mg FeSO4 or 19 mg elemental iron/d), we still saw an improvement in Fe status with supplementation, and no side-effects were reported with this dose. FeSO4 is highly-absorbable (Davila-Hicks et al. 2004), is 3–4x more absorbable than ferric preparations, and its bioavailability is comparable to supplements containing heme Fe (Swain et al. 2007).
Iron deficiency anemia in males: a dosing dilemma?
Published in Journal of Community Hospital Internal Medicine Perspectives, 2021
Abu Baker Sheikh, Nismat Javed, Zainab Ijaz, Venus Barlas, Rahul Shekhar, Blavir Rukov
Despite this factor, the routine practice is to address the amount of elemental iron needed to correct the anemia. The adult dose of elemental iron is 150 to 200 mg daily for 3 months. Oral ferrous sulfate is the most commonly used formulation. The quantity of elemental iron in one 325 mg tablet is about 65 mg; therefore, the oral form is recommended for use every eight hours [15]. In that case, the total amount supplied to the body in one day would be 195 mg. However, only 2% to 13% of the supplied elemental iron is absorbed with food, and 5% to 28% is absorbed without food [16]. Even if maximal absorption rates were achieved, the additional requirement to correct anemia would still not be met. However, it was found that when the total amount of oral ferrous sulfate prescribed in a day increased, it was associated with adverse effects such as nausea, vomiting, tarry stools, dose-related constipation, and taste changes [17]. These adverse effects can cause non-compliance in many patients.
Ferumoxytol for the treatment of iron deficiency anemia
Published in Expert Review of Hematology, 2018
Michael Auerbach, Glenn M. Chertow, Mitchell Rosner
In summary, ferumoxytol, an intravenous iron formulation originally designed for imaging, has been proved to be a safe and effective means of iron repletion in persons with iron deficiency anemia. Its early history as a therapeutic agent was compromised by an excessive rapid rate of infusion (30 mg/1 mL per sec = total dose 510 mg over 17 sec); slower rates of infusion are mandatory. We routinely administer 510 mg as a 3- to 5-min bolus injection or 1020 mg as a 15-min infusion. However, we recommend that the 510 mg 15 min on label infusion rate be adhered to unless there is familiarity with the bolus injection, the 1020 mg total dose infusion or as part of a clinical trial. Relative to other IV iron formulations, ferumoxytol infusion yields relatively low quantities of labile free iron; hypersensitivity or anaphylactoid reactions are extremely rare. The ability to administer relatively high doses of elemental iron in a single infusion, the absence of hypophosphatemia, and a favorable safety profile should make ferumoxytol a high-value choice for IV iron repletion in a wide range of clinical settings. Coming full circle, optimal strategies for application of ferumoxytol-enhanced imaging remain to be determined.